Jenifer Michelle Brown, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperaldosteronism | 13 | 2024 | 247 | 3.680 |
Why?
|
Aldosterone | 16 | 2024 | 869 | 2.080 |
Why?
|
Hypertension | 13 | 2024 | 8532 | 1.050 |
Why?
|
Renin | 9 | 2024 | 640 | 1.020 |
Why?
|
Parathyroid Hormone | 7 | 2024 | 1803 | 0.980 |
Why?
|
Renin-Angiotensin System | 5 | 2018 | 737 | 0.940 |
Why?
|
Ammonia | 2 | 2023 | 237 | 0.870 |
Why?
|
Myocardial Perfusion Imaging | 8 | 2024 | 575 | 0.810 |
Why?
|
Coronary Artery Disease | 10 | 2024 | 6403 | 0.640 |
Why?
|
Fractional Flow Reserve, Myocardial | 5 | 2024 | 324 | 0.580 |
Why?
|
Myocardial Ischemia | 3 | 2023 | 2110 | 0.580 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2022 | 163 | 0.560 |
Why?
|
Coronary Circulation | 10 | 2024 | 1569 | 0.550 |
Why?
|
Atherosclerosis | 4 | 2022 | 3400 | 0.510 |
Why?
|
Angiotensin II | 4 | 2018 | 849 | 0.510 |
Why?
|
Renal Plasma Flow | 2 | 2017 | 27 | 0.500 |
Why?
|
Captopril | 1 | 2013 | 265 | 0.420 |
Why?
|
Spironolactone | 2 | 2024 | 409 | 0.380 |
Why?
|
Heart Failure | 4 | 2024 | 11670 | 0.370 |
Why?
|
Positron-Emission Tomography | 10 | 2024 | 6483 | 0.330 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1517 | 0.290 |
Why?
|
Kidney | 4 | 2023 | 7044 | 0.290 |
Why?
|
Receptors, Mineralocorticoid | 2 | 2017 | 163 | 0.270 |
Why?
|
Cardiovascular Diseases | 6 | 2023 | 15498 | 0.260 |
Why?
|
Potassium | 2 | 2020 | 1311 | 0.240 |
Why?
|
Microcirculation | 3 | 2024 | 1272 | 0.230 |
Why?
|
Osteoporosis | 1 | 2014 | 1604 | 0.230 |
Why?
|
Calcium | 5 | 2024 | 5717 | 0.230 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5031 | 0.220 |
Why?
|
Hypocalcemia | 1 | 2024 | 200 | 0.210 |
Why?
|
Amiloride | 1 | 2022 | 116 | 0.210 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 36 | 0.210 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2024 | 618 | 0.200 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 2 | 2024 | 1068 | 0.200 |
Why?
|
Vascular Resistance | 1 | 2024 | 930 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 558 | 0.180 |
Why?
|
Heart Atria | 2 | 2023 | 1333 | 0.170 |
Why?
|
Cross-Sectional Studies | 8 | 2023 | 26065 | 0.160 |
Why?
|
Coronary Vessels | 4 | 2024 | 3095 | 0.160 |
Why?
|
Minerals | 2 | 2018 | 283 | 0.160 |
Why?
|
Perfusion | 1 | 2023 | 1373 | 0.160 |
Why?
|
Anemia, Pernicious | 1 | 2018 | 15 | 0.150 |
Why?
|
Humans | 44 | 2024 | 760740 | 0.150 |
Why?
|
Expert Testimony | 1 | 2020 | 364 | 0.150 |
Why?
|
Vitamin D | 4 | 2018 | 3301 | 0.150 |
Why?
|
Research Report | 1 | 2020 | 367 | 0.140 |
Why?
|
Foreign-Body Migration | 1 | 2018 | 219 | 0.140 |
Why?
|
Female | 29 | 2024 | 392203 | 0.140 |
Why?
|
Physical Examination | 1 | 2022 | 1254 | 0.130 |
Why?
|
Middle Aged | 22 | 2024 | 220603 | 0.130 |
Why?
|
Calcitriol | 1 | 2018 | 296 | 0.130 |
Why?
|
Fibrosis | 1 | 2023 | 2047 | 0.130 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2016 | 78 | 0.130 |
Why?
|
Blood Pressure | 5 | 2024 | 8473 | 0.130 |
Why?
|
Male | 25 | 2024 | 360402 | 0.120 |
Why?
|
p-Aminohippuric Acid | 1 | 2014 | 36 | 0.120 |
Why?
|
Pre-Eclampsia | 1 | 2024 | 1230 | 0.120 |
Why?
|
Sodium, Dietary | 2 | 2017 | 425 | 0.120 |
Why?
|
Ischemia | 1 | 2022 | 1885 | 0.110 |
Why?
|
Device Removal | 1 | 2018 | 629 | 0.110 |
Why?
|
Calcium Channel Blockers | 1 | 2016 | 694 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2023 | 5239 | 0.100 |
Why?
|
Diet, Sodium-Restricted | 1 | 2014 | 291 | 0.100 |
Why?
|
Psoriasis | 1 | 2020 | 944 | 0.100 |
Why?
|
Parathyroid Glands | 1 | 2013 | 518 | 0.100 |
Why?
|
Aged | 15 | 2024 | 169092 | 0.090 |
Why?
|
Stroke Volume | 2 | 2022 | 5486 | 0.090 |
Why?
|
Fibroblast Growth Factors | 1 | 2017 | 865 | 0.090 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2011 | 166 | 0.090 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2917 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2020 | 12143 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1948 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3117 | 0.090 |
Why?
|
Diuretics | 1 | 2013 | 611 | 0.090 |
Why?
|
Pituitary Gland | 1 | 2013 | 635 | 0.090 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 654 | 0.090 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 2118 | 0.080 |
Why?
|
Glomerular Filtration Rate | 2 | 2017 | 2174 | 0.080 |
Why?
|
Cardiology | 1 | 2020 | 1656 | 0.080 |
Why?
|
Predictive Value of Tests | 2 | 2022 | 15250 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2024 | 80583 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2152 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4218 | 0.080 |
Why?
|
Linear Models | 2 | 2017 | 5866 | 0.070 |
Why?
|
Hemodynamics | 2 | 2018 | 4160 | 0.070 |
Why?
|
Hormone Replacement Therapy | 1 | 2013 | 751 | 0.070 |
Why?
|
Adiposity | 1 | 2017 | 1879 | 0.070 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2013 | 1148 | 0.070 |
Why?
|
Stents | 1 | 2018 | 3177 | 0.070 |
Why?
|
Hypogonadism | 1 | 2013 | 798 | 0.070 |
Why?
|
Aged, 80 and over | 5 | 2024 | 58919 | 0.070 |
Why?
|
Heart Ventricles | 1 | 2018 | 3796 | 0.070 |
Why?
|
Prevalence | 2 | 2020 | 15702 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15829 | 0.070 |
Why?
|
Recombination, Genetic | 1 | 2011 | 1519 | 0.070 |
Why?
|
Prognosis | 4 | 2024 | 29601 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20077 | 0.060 |
Why?
|
Adult | 10 | 2024 | 220995 | 0.060 |
Why?
|
Risk Factors | 5 | 2022 | 74128 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12043 | 0.060 |
Why?
|
Antihypertensive Agents | 1 | 2013 | 2018 | 0.060 |
Why?
|
Dideoxynucleosides | 1 | 2023 | 135 | 0.050 |
Why?
|
Cohort Studies | 3 | 2023 | 41464 | 0.050 |
Why?
|
Bone Density | 1 | 2016 | 3548 | 0.050 |
Why?
|
Cell Cycle | 1 | 2011 | 2929 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 1 | 2011 | 3730 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 366 | 0.050 |
Why?
|
Adrenal Glands | 1 | 2024 | 552 | 0.050 |
Why?
|
Magnetic Resonance Angiography | 2 | 2018 | 1431 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 10754 | 0.050 |
Why?
|
Oxazines | 1 | 2023 | 349 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14599 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11458 | 0.050 |
Why?
|
Alanine | 1 | 2023 | 609 | 0.050 |
Why?
|
Drug Substitution | 1 | 2023 | 290 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 287 | 0.050 |
Why?
|
Committee Membership | 1 | 2020 | 17 | 0.050 |
Why?
|
Microvessels | 1 | 2024 | 577 | 0.040 |
Why?
|
Incidence | 1 | 2017 | 21339 | 0.040 |
Why?
|
Iliac Vein | 1 | 2018 | 70 | 0.040 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2023 | 851 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 808 | 0.040 |
Why?
|
Retinal Vessels | 1 | 2024 | 853 | 0.040 |
Why?
|
Syphilis Serodiagnosis | 1 | 2018 | 37 | 0.040 |
Why?
|
Methylmalonic Acid | 1 | 2018 | 49 | 0.040 |
Why?
|
Treponema pallidum | 1 | 2018 | 47 | 0.040 |
Why?
|
Drug Combinations | 1 | 2023 | 2048 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18381 | 0.040 |
Why?
|
Postpartum Period | 1 | 2024 | 1178 | 0.040 |
Why?
|
HIV Infections | 1 | 2023 | 17342 | 0.030 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2252 | 0.030 |
Why?
|
Sensation Disorders | 1 | 2018 | 160 | 0.030 |
Why?
|
Dexamethasone | 1 | 2024 | 1946 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2021 | 973 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2018 | 555 | 0.030 |
Why?
|
Ventricular Remodeling | 1 | 2023 | 1265 | 0.030 |
Why?
|
United States | 2 | 2020 | 72292 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54364 | 0.030 |
Why?
|
Critical Pathways | 1 | 2018 | 474 | 0.030 |
Why?
|
Vitamin B 12 | 1 | 2018 | 524 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2018 | 915 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2023 | 22153 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1110 | 0.030 |
Why?
|
Water-Electrolyte Balance | 1 | 2015 | 325 | 0.030 |
Why?
|
Regional Blood Flow | 1 | 2017 | 1496 | 0.030 |
Why?
|
Postural Balance | 1 | 2018 | 622 | 0.030 |
Why?
|
Piperazines | 1 | 2023 | 2521 | 0.030 |
Why?
|
Blood Vessels | 1 | 2018 | 1112 | 0.020 |
Why?
|
Myocardium | 1 | 2024 | 4725 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2023 | 4470 | 0.020 |
Why?
|
Metabolome | 1 | 2018 | 988 | 0.020 |
Why?
|
Chromosome Breakage | 1 | 2011 | 159 | 0.020 |
Why?
|
S Phase | 1 | 2011 | 421 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2022 | 20556 | 0.020 |
Why?
|
Vitamin D Deficiency | 1 | 2018 | 1388 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 4524 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3873 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12448 | 0.020 |
Why?
|
Tamoxifen | 1 | 2011 | 965 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8209 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2011 | 2063 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3591 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2011 | 1149 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 23974 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2011 | 2208 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12966 | 0.010 |
Why?
|
Pregnancy | 1 | 2024 | 29869 | 0.010 |
Why?
|
Obesity | 1 | 2024 | 12934 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16572 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42193 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12977 | 0.010 |
Why?
|
Young Adult | 1 | 2022 | 59191 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 16968 | 0.010 |
Why?
|
Signal Transduction | 1 | 2015 | 23415 | 0.010 |
Why?
|
Brain | 1 | 2018 | 27100 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36401 | 0.010 |
Why?
|
Time Factors | 1 | 2011 | 39908 | 0.010 |
Why?
|
Mutation | 1 | 2013 | 30015 | 0.000 |
Why?
|
Treatment Outcome | 1 | 2013 | 64572 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 88247 | 0.000 |
Why?
|
Animals | 1 | 2015 | 168202 | 0.000 |
Why?
|